Ursodeoxycholic acid combined with percutaneous transhepatic balloon dilation for management of gallstones after elimination of common bile duct stones

Table 1 Baseline characteristics of patients

No.	Gender /age	CBD/gallbladder
		Number of stones	Diameter of the largest stone (mm)	Diameter of the largest balloon (mm)
1	F/58	2/2	10/6	12/8
2	M/45	3/1	15/7	16/8
3	M/75	1/2	25/10	24/10
4	F/67	1/1	20/8	20/8
5	F/64	3/2	20/9	20/10
6	M/68	2/2	21/10	20/10
7	F/73	3/1	22/14	20/-
8	F/76	3/2	20/11	20/12
9	M/86	2/1	21/10	20/10
10	F/81	3/1	19/8	18/8
11	F/67	1/2	20/10	20/10
12	F/72	2/1	21/12	20/12
13	M/76	2/3	18/15	18/-
14	F/65	3/1	18/12	18/12
15	M/63	1/1	20/12	20/12

CBD: Common bile duct.

Table 2 Operative parameters

No.	Primary technical success	Secondary technical success	Adverse events	Treatment
1	Yes	Yes	No
2	Yes	Yes	Fever	Medication
3	Yes	Yes	No
4	Yes	Yes	No
5	Yes	Yes	Abdominal distension	Medication
6	Yes	Yes	No
7	Yes	No	No
8	Yes	Yes	No
9	Yes	Yes	No
10	Yes	Yes	No
11	Yes	Yes	Abdominal pain	Medication
12	Yes	Yes	No
13	Yes	No	No
14	Yes	Yes	No
15	Yes	Yes	No

Table 3 Laboratory tests pre and post-intervention

	Pre-intervention	2 wk after intervention	t	P value
ALT (U/L)	98.93 ± 24.47	36.13 ± 8.99	10.41	< 0.001
TBIL (μmol/L)	39.40 ± 7.76	21.47 ± 12.09	6.52	< 0.001
Amylase (U/L)	80.73 ± 14.94	82.07 ± 17.77	0.34	0.741
WBC (× 109/L)	11.58 ± 1.45	7.65 ± 2.11	5.90	< 0.001
HGB (g/L)	122.93 ± 8.66	118.80 ± 13.39	1.52	0.150

ALT: Alanine transaminase; HGB: Hemoglobin; TBIL: Total bilirubin; WBC: White blood cell.